header logo image


Page 223«..1020..222223224225..230240..»

Genetic Counseling, the barriers to access, and how we overcome them – WFMZ Allentown

May 2nd, 2021 1:57 am

ORLANDO, Fla., April 30, 2021 /PRNewswire-PRWeb/ --What is genetic counseling?

Genetic counseling is an integral part of the genetic screening, testing, and diagnosis process. It provides important services for individuals and families looking to understand more about their genetic health, their potential risks for developing a rare disease, and, in some cases, to understand a confirmed diagnosis of a rare disease as well.

Genetic counseling provides important information and knowledge about the causes and possible symptoms of rare diseases. It also helps put a patient's family medical history, their own medical history, and their symptoms within the context of a rare disease diagnosis. It improves the accuracy of the genetic diagnosis process and helps patients gain access to more targeted genetic testing for a more accurate result and diagnosis.

It is also important for the role it plays in providing patients and families with emotional support during challenging and sometimes stressful processes. It helps connect patients to rare disease networks and support groups as well.

Genetic counseling acts as a bridge between a patient and the medical world - it translates medical jargon, test results and coordinates the different parts of a rare disease patient's care management and possible treatment options.

Barriers to accessing genetic counseling

There are several main barriers to accessing genetic counseling. The implications of these barriers can have profound and long-lasting effects on the diagnosis and care of rare disease patients.

The diagnosis of rare diseases is already fraught with misdiagnosis and delayed diagnosis - some patients face a wait of anywhere between 4-8 years to receive a correct diagnosis. Part of this delay is caused by a lack of access to genetic counseling services and support.

This delay in reaching a diagnosis can, in turn, lead to delays in treatment and support for rare disease patients. Improving patient outcomes starts with an accurate and timely diagnosis.

Location

For many people, location is a considerable obstacle to accessing genetic counseling services. This is a particular problem for people who live in rural or remote areas. Still, even with larger urban areas and centers, location can be a real barrier to genetic counseling services.

Availability

As awareness about genetic screening, genetic testing, and rare diseases increases, so does the demand for genetic counseling. This creates increased pressure on a much-needed service and can lead to long wait times for appointments. This, in turn, creates a barrier to access and delays access to genetic counseling.

Cost

For some patients, the cost of genetic counseling, including transport costs to get there, can create an insurmountable barrier to accessing the service.

Awareness

Not everyone is aware of the importance of genetic counseling during the genetic diagnosis process. Not everyone is aware of the full range of services and support provided by a genetic counselor. For others, there is a barrier in understanding how and where they can access genetic counseling services and whether overcoming these barriers is worth it.

Overcoming barriers to genetic counseling

Increasing accessibility to genetic counseling services is important if we continue to raise awareness around rare diseases and ensure that rare disease patients get an accurate diagnosis fast. The faster patients receive a diagnosis, the faster they can manage their condition and related symptoms and improve their long-term outcomes.

So, how do we achieve this?

Online or virtual genetic counseling is one solution that removes all of the current barriers to accessing genetic counseling - location, availability, cost, and awareness - and ensures any patient from anywhere in the world can connect with a network of global genetic counselors and experts, from the comfort of their own home.

Online genetic counseling is easy to access. All it requires is a connected device with video. This means no traveling is involved, no logistical challenges to overcome, and it means accessing genetic counseling from a place and time that works for the patient and their family. It also removes scheduling conflicts and tries to fit genetic counseling and traveling to it into a family's schedule when moved online. There is greater flexibility in where and when, and this benefits everyone.

Moving genetic counseling online also increases availability - it removes wait times for a genetic counselor nearby and allows patients to look further afield for a genetic counselor, regardless of where the patient or counselor is in the world. This creates access to a broader pool of genetic experts and helps patients secure appointments faster. It also helps reduce costs and may ensure more competitive pricing for genetic counseling services as well.

Also, moving genetic counseling online should help raise awareness about its crucial and essential services for rare disease patients and their families. Greater accessibility naturally means greater awareness.

The FDNA Telehealth platform is designed to connect rare disease patients to a global network of genetic experts almost immediately. From the first meeting with a genetic counselor to more specific guidance with genetic testing and analysis options to understand how to manage a rare disease, online genetic counseling delivers help, information, and support fast.

Media Contact

Ido Rabiner, FDNA Telehealth, +1 877-327-0735, ido.rabiner@fdna.com

SOURCE FDNA Telehealth

Excerpt from:
Genetic Counseling, the barriers to access, and how we overcome them - WFMZ Allentown

Read More...

Diagnosed with a rare genetic condition, young Winston Salem boy improves with new medication – WXII12 Winston-Salem

May 2nd, 2021 1:57 am

This past year was tough on us all but living through a pandemic was not the only challenge the Whitler family had to overcome.Joanna Whitler says she was shocked when she found out that 6-month-old baby Luke had a rare genetic medical condition called spinal muscular atrophy also known as SMA.The condition impairs an individuals muscles and motor neurons by not producing enough protein to keep up with the bodys functions.After undergoing multiple treatments, Luke is now taking a new, recently FDA approved medicine called Evrysdi. Which is the first and only take-home medicine to treat FDA. After a short time taking it, his family is already seeing multiple improvements. During Christmas this year, Bodhi, his older brother, asked Santa for a PJ mask doll and for Luke to crawl. And he got a PJ mask doll on Christmas, Luke did not crawl until March, but he is now crawling, Whitler said. The family says they hope the medicine will continue to make Luke improve and that his story will help spread awareness for SMA.

This past year was tough on us all but living through a pandemic was not the only challenge the Whitler family had to overcome.

Joanna Whitler says she was shocked when she found out that 6-month-old baby Luke had a rare genetic medical condition called spinal muscular atrophy also known as SMA.

The condition impairs an individuals muscles and motor neurons by not producing enough protein to keep up with the bodys functions.

After undergoing multiple treatments, Luke is now taking a new, recently FDA approved medicine called Evrysdi. Which is the first and only take-home medicine to treat FDA.

After a short time taking it, his family is already seeing multiple improvements.

During Christmas this year, Bodhi, his older brother, asked Santa for a PJ mask doll and for Luke to crawl. And he got a PJ mask doll on Christmas, Luke did not crawl until March, but he is now crawling, Whitler said.

The family says they hope the medicine will continue to make Luke improve and that his story will help spread awareness for SMA.

Visit link:
Diagnosed with a rare genetic condition, young Winston Salem boy improves with new medication - WXII12 Winston-Salem

Read More...

Phenotypic Stratification of Patients With Painful Neuropathy May Predict Response to Therapy – Clinical Pain Advisor

May 2nd, 2021 1:55 am

A transetiologic, phenotype-based approach was associated with response to treatment and may improve the management of neuropathic pain. These findings were published in the journal Pain.

Patients (n=628) with probable or definite neuropathic pain were recruited from the Pain Center at Ambroise Par Hospital in France. All patients were assessed by a standard clinical neurologic examination. They then rated their pain during the past 24 hours on an 11-point numerical scale and completed the Neuropathic Pain Symptom Inventory (NPSI).

A clustering approach was used to stratify patients by pain phenotypes. Researchers used data from a previous study of patients (n=97) with neuropathic pain who were randomly assigned to receive botulinum toxin A (BTX-A) or placebo to assess whether patient clusters would be more or less responsive to BTX-A treatment.

Continue Reading

The internal and BTX-A cohorts comprised patients who had a mean age of 56.4 (15.2) and 52.3 (16.1) years, 51.9% and 50.5% were women, their duration of pain was 64.8 (74.7) and 63 (67) months, and their pain intensity was 6.4 (1.7) and 6.4 (1.6) points, respectively.

Among the internal cohort, 3 major clusters were identified. Patients in cluster 1 (31.4%) had pinpointed pain with above-average paresthesia or dysesthesia and below-average evoked pain. Patients in cluster 2 (30.4%) had evoked pain with above-average pain that was provoked by brushing, cold, pressure, or electric shocks, and below-average deep pain and paresthesia or dysesthesia. Patients in cluster 3 (38.2%) comprised patients who had deep pain that felt like squeezing and above-average pressure with below-average paresthesia or dysesthesia.

Patients in the BTX-A cohort were stratified into 3 patient clusters. Patients in group 2 had a significant group (F, 6.71; P =.013) and group by time interaction (F, 2.24; P =.009). Similarly, patients in cluster 3 had both a significant group (F, 4.41; P =.042) and group by time interaction (F, 2.01; P =.021). BTX-A therapy did not have a significant effect compared with placebo among patients in cluster 1 (F, 0.35; P =.56).

This study was based on post hoc analyses and requires validation in a prospective cohort.

These findings suggest that a transetiologic, phenotype-based approach may have the potential to improve treatment selection for patients with painful neuropathy.

Bouhassira D, Branders S, Attal N, et al. Stratification of patients based on the Neuropathic Pain Symptom Inventory: development and validation of a new algorithm. Pain. 2021;162(4):1038-1046. doi:10.1097/j.pain.0000000000002130

Follow this link:
Phenotypic Stratification of Patients With Painful Neuropathy May Predict Response to Therapy - Clinical Pain Advisor

Read More...

Peripheral Neuropathy Treatment Market: Development, Growth, Trends, Demand, Analysis and Forecast 2026 KSU | The Sentinel Newspaper – KSU | The…

May 2nd, 2021 1:55 am

Coherentmarketinsights.Com Presents Global Peripheral Neuropathy Treatment Market Research Report 2019 New Research To Its Studies Database

The global Peripheral Neuropathy Treatment Market research report highlights the need for up-to-date market data for the business management that will offer development and profitability of the global Peripheral Neuropathy Treatment market. The research report presents all the essential facts and figures on drifts & growths. It emphasizes technologies & capacities, materials & markets, and the unpredictable structure of the Peripheral Neuropathy Treatment market. In addition, it also highlights the dominating players in the market joined with their market share. The well-established players in the market are Abbott, Bristol Myers Squibb, Cipla Limited, Eli Lilly and Company, GlaxoSmithKline plc., Lupin Limited, Merck and Co. Inc., Novartis AG, Pfizer Inc., Dr. Reddys Laboratories, Mylan NV, Johnson & Johnson Services Inc., and Teva Pharmaceutical Industries Ltd. among others.

Get PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4363

The global Peripheral Neuropathy Treatment Market report portrays the best approaches to assess the global Peripheral Neuropathy Treatment market. It offers reliable facts and extensive analysis of the global Peripheral Neuropathy Treatment Market. The report presents a summary of the global Peripheral Neuropathy Treatment industry, embracing categorizations, applications, and industry chain structure. The study also represents a thorough analysis including significant insights, industry-legalized figures, and facts of the global Peripheral Neuropathy Treatment market.

Furthermore, the study also assesses the principal aspects of the market that entails revenue, demand, gross value, growth rate, cost, capability, market share, import, gross margin, expenditure, export, manufacture, supply, and so on. A number of methodological tools are used in the global Peripheral Neuropathy Treatment market analysis. It offers a complete analysis of the market statistics and the estimation of the global Peripheral Neuropathy Treatment industry players along with their market scope.

Global Peripheral Neuropathy Treatment market size expected to reach xx Million USD by 2027, from xx Million USD in 2019, at a CAGR of xx% during the forecast period (2019-2027). In this study report, 2019 has been considered as the base year, 2019 as the Estimated Year, (2013-2017) as the History Year and 2019 to 2027 as the forecast period to estimate the market size for Peripheral Neuropathy Treatment.

GlobalPeripheral Neuropathy Treatment Market Segmentations

The segmentation chapter allows the reader to understand aspects of the globalPeripheral Neuropathy Treatment market such as products/services, available technologies, and applications. This chapter is written in a way that describes the years of development and the process that will take place in the years to come. Research reports also provide insightful information on emerging trends that can define the progress of these segments over the next few years.

Peripheral Neuropathy Treatment Consumption Breakdown Data by Region

The Report Offers The Following Study Objectives:

Get Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/4363

Discovering the Importance of this Peripheral Neuropathy Treatment industry research report:

The Peripheral Neuropathy Treatment Market report emphasizes various procedures and approaches endorsed by the key players to make crucial business decisions.

It describes parameters such as capacity, production value in a statistical format that is accurately comprehended by the readers.

It identifies the growth of nature having a forecast period of 7 years.

The report influences advantageous prospects to convert into Peripheral Neuropathy Treatment business acquisitions.

It reveals product overview, business overview, Peripheral Neuropathy Treatment market share, demand and supply ratio, supply chain analysis, and import/export details.

Peripheral Neuropathy Treatment Market is a comprehensive collection of information and figures in the form of graphs, pie charts, and tables. Data is specifically acquired from secondary sources including the internet, journals, magazines, and press releases. All the retrieved data is validated using primary interviews and questionnaires.

Report Covers Impacts of COVID-19 to the market

The on-going pandemic has overhauled various facets of the market. This research report provides financial impacts and market disturbancein thePeripheral Neuropathy Treatment market. It also includes an analysis of the potentially lucrative opportunities and challenges in the foreseeable future. Coherent Market Insights has interviewed various delegates of the industry and got involved in the primary and secondary research to confer the clients with information and strategies to fight against the market challenges amidst and after the COVID-19 pandemic.

Table of Contents :

Global Peripheral Neuropathy Treatment Sales Market Report 2018 Mainly Covers Following Chapters:

1. Peripheral Neuropathy Treatment Overview(Product Overview, Scope and Classification of Peripheral Neuropathy Treatment), Type and Application of Peripheral Neuropathy Treatment, Peripheral Neuropathy Treatment Market by Regions;2. Global Peripheral Neuropathy Treatment Competition by Manufacturers, Type, and Application with (Sales and Market Share, Revenue and Share, Volume and Value) by Manufacturers, by Type, by Regions and by Application;3. United States Peripheral Neuropathy Treatment (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);4. China Peripheral Neuropathy Treatment (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);5. Europe Peripheral Neuropathy Treatment (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);6. Japan Peripheral Neuropathy Treatment (Volume, Value and Sales Price, Revenue and Growth Rate) by Manufacturers, Type, Application (2011-2018);7. Global Peripheral Neuropathy Treatment Manufacturers Analysis(Company Basic Information, Manufacturing Base and Competitors, Product Type, Application and Specification), Peripheral Neuropathy Treatment Sales, Revenue, Price and Gross Margin (2011-2018), Main Business/Business Overview;8. Peripheral Neuropathy Treatment Manufacturing Cost Analysis, Key Raw Materials Analysis(Key Raw Materials, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials), Proportion of Manufacturing Cost Structure(Labour Cost, Raw Materials, Manufacturing Process Analysis of Peripheral Neuropathy Treatment);9. Industrial Chain Analysis, Upstream Raw Materials Sourcing, Sourcing Strategy and Downstream Buyers;10. Marketing Strategy Analysis, Distributors/Traders with Marketing Channel(Direct Marketing, Indirect Marketing, Marketing Channel Development Trend), Market Positioning(Pricing Strategy, Brand Strategy, Target Client), Distributors/Traders List;11. Market Effect Factors Analysis (Technology Progress/Risk, Substitutes Threat, Technology Progress in Related Industry), Consumer Needs/Customer Preference Change, Economic/Political Environmental Change;12. Global Peripheral Neuropathy Treatment Market Sales, Revenue Forecast (2018-2021) by Regions, by Type, by Application;13. Appendix, Disclosure Section, Research Methodology, Data Source, Disclaimer.

Get Discount For Buyers UPTO 30% OFF On Any Research Report : https://www.coherentmarketinsights.com/insight/request-discount/4363

In conclusion, the Global Peripheral Neuropathy Treatment Market report presents the complete analysis of the modern market depend on leading players, present, past and upcoming period information which will provide as a valuable guide for all the Peripheral Neuropathy Treatment business associate.

Thanks for reading this Report; you can also get specific chapter-wise, section wise or region-wise reports.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

See more here:
Peripheral Neuropathy Treatment Market: Development, Growth, Trends, Demand, Analysis and Forecast 2026 KSU | The Sentinel Newspaper - KSU | The...

Read More...

Diabetic Neuropathy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 The Courier – The Courier

May 2nd, 2021 1:55 am

Most Recent Report On The Global Diabetic Neuropathy Market

The Diabetic Neuropathy Marketreport provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations

Diabetic Neuropathy Market report provides a thoroughly researched abstract of the key players with considerable shareholdings at a global level regarding demand, sales, and income by providing better products and services. Research Report outlines a forecast for the Diabetic Neuropathy market between 2020 and 2027. In terms of value, the Diabetic Neuropathy industry is expected to register a steady CAGR during the forecast period.

Diabetic NeuropathyMarket competition by top manufacturers as follows:Eli Lilly and Company, GlaxoSmithKline, Pfizer, Johnson & Johnson and Janssen Pharmaceuticals.

The Download PDF brochure only consists of a Table of Content, Research Framework, and Research Methodology.

Get PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/213

Valuable Data included in the report:

In-depth analysis of the sales strategies adopted by domestic as well as global market playersLatest innovations in the Diabetic Neuropathy market and its impact on market growthAll-round evaluation of the different factors expected to influence the market dynamicsPricing and marketing strategies adopted by top-tier companiesEvaluation of the micro and macro-economic factors that are anticipated to shape the future of the Diabetic Neuropathy market

Competitive Outlook

The presented business intelligence report includes a SWOT analysis for the leading market players along with vital information including, revenue analysis, market share, pricing strategy of each market player.

Regional analysis includes

North AmericaLatin AmericaEuropeSouth AsiaEast AsiaOceaniaThe Middle East and Africa

Browse Diabetic Neuropathy Research Report:Diabetic Neuropathy Market

The researchers have analyzed macro-economic factors such as political, economic, social, technological, environmental, and legal developments, to derive the drivers and restraints of the Diabetic Neuropathy Market. Over the top investigation of the political and financial scene of every single significant district has been done to introduce the components that will prompt the market income. Then again, customer conduct over the globe has been investigated to comprehend the conceivable development restrictions, notwithstanding other large scale factors. Understanding the restraining factors empowers market players to mitigate the possible risks that they may have to deal with during the forecast period 2016 2026.

The report provides a comprehensive study of the Diabetic Neuropathy Market, with details ranging from assessment of companies to trends to geography-specific drivers and restraints. Moreover, the examination presents segmental features and serious scenes concerning every geology. Authored by researchers after extensive analysis, the report is suffused with key insights into the global Diabetic Neuropathy Market and will ensure that the readers gain a comprehensive understanding of the direction the Diabetic Neuropathy Market is headed in.

Important Queries Addressed in the report:

With a systematic and methodic approach, our analysts collect data from credible primary and secondary sources. In addition, we offer the most efficient after-sales services to our customers and address their problems without any delay.

Highlights of TOC:

Overview: Presents a broad overview of the Diabetic Neuropathy Market, acting as a snapshot of the elaborate study that follows.

Market Dynamics: A straightforward discussion about key drivers, restraints, challenges, trends, and opportunities of the Diabetic Neuropathy Market.

Product Segments: Explores the market development of the wide assortment of items offered by associations, and how they charge with end-clients.

Application Segments: This section studies the key end-use applications that contribute to the market growth and the emerging opportunities to the Diabetic Neuropathy Market.

Geological Segments: Each territorial market with an area explicit investigation of each section is deliberately evaluated for understanding its current and future development situations.

Company Profiles: Leading and emerging players of the Diabetic Neuropathy Market are thoroughly profiled in the report based on their market share, market served, products, applications, regional growth, and other factors.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/213

*The discount is offered on the Standard Price of the report.

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)

provides COVID-19 Vaccine Tracker for all the latest updates about COVID-19 Vaccine.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Tel: +1-206-701-6702Email: sales@coherentmarketinsights.com

Read the original here:
Diabetic Neuropathy Market: Demand, Insights, Analysis, Opportunities, Segmentation and Forecast to 2026 The Courier - The Courier

Read More...

Leber’s Hereditary Optic Neuropathy Drug Market Size and Forecast 2027 | Top Key Players Alkeus Pharmaceuticals, Ixchel Pharma, LLC, Biovista Inc.,…

May 2nd, 2021 1:55 am

The Lebers Hereditary Optic Neuropathy Drug Market research report aims to provide the readers with an accurate and data-based assessment of the current market conditions over the forecast period of 2021 to 2027. It also provides valuable insight into the market performance in years to come, drawn from a careful assessment of various economic, social, technological, political, and demographic factors.

The study analyzes various drivers and restraints for stakeholders and players in the Lebers Hereditary Optic Neuropathy Drug market and assesses their effects on general demand dynamics. This business intelligence report can prove to be a powerful resource for players in the Lebers Hereditary Optic Neuropathy Drug market to help guide their business development strategies and to make informed decisions.

Request to Get the PDF Sample of the Report @ https://reportsglobe.com/download-sample/?rid=105685

Top Key Players Profiled in this report are:

The research report assesses detailed historical data on production volume, capacity, demand, and supply chain logistics in the Lebers Hereditary Optic Neuropathy Drug market to assess the strong impact of the Covid-19 pandemic on the market. . It analyzes the evolution of trends and takes into account recent developments likely to affect the market scenario in the years to come.

Lebers Hereditary Optic Neuropathy Drug Market Segmentation:

Based on Type

Based on Application

Regional Analysis:

The report provides information about the market area, which is further subdivided into sub-regions and countries. In addition to market share in each country and subregion, this chapter of this report also provides information on profit opportunities. This chapter of the report mentions the share and market growth rate of each region, country, and sub-region in the estimated time period.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=105685

Some of the crucial questions answered in the professional intelligence study on Lebers Hereditary Optic Neuropathy Drug market include:

View market snapshot before purchasing @ https://reportsglobe.com/product/global-lebers-hereditary-optic-neuropathy-drug-market-insight-and-forecast/

Please contact us if you would like more information about the report. If you have any special requirements and would like customization, please let us know. We will then offer the report as you wish.

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Sarkari Results, Thrive Market Research

Originally posted here:
Leber's Hereditary Optic Neuropathy Drug Market Size and Forecast 2027 | Top Key Players Alkeus Pharmaceuticals, Ixchel Pharma, LLC, Biovista Inc.,...

Read More...

Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women…

May 2nd, 2021 1:53 am

PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial evaluating the safety and efficacy of Twirla® (levonorgestrel and ethinyl estradiol) transdermal system in women with BMI < 25 kg/m2 and women with BMI 25-30 kg/m2 will be presented at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting from April 30 – May 2.

Read the original:
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women...

Read More...

22nd Century Group Welcomes Ban on Menthol Cigarettes and Anticipates Further Standards as FDA Commissioner Reports Nicotine Cap on Combustibles…

May 2nd, 2021 1:53 am

Applauds Decisive Move and Commitment by FDA to Advance Rule Banning Menthol As First Step to Reduce Addiction, Improve Quitting, Reduce Youth Initiation and Reduced Disparities; Movement on Nicotine Cap by FDA Expected to be Forthcoming

Excerpt from:
22nd Century Group Welcomes Ban on Menthol Cigarettes and Anticipates Further Standards as FDA Commissioner Reports Nicotine Cap on Combustibles...

Read More...

Santhera Completes Capital Increases for Financing Arrangements

May 2nd, 2021 1:53 am

Pratteln, Switzerland, April 30, 2021 – Santhera Pharmaceuticals (SIX: SANN) announces that it has issued 2,312,000 treasury shares.

More:
Santhera Completes Capital Increases for Financing Arrangements

Read More...

Annual General Meeting of April 30, 2021

May 2nd, 2021 1:53 am

Annual General Meeting of April 30, 2021

Excerpt from:
Annual General Meeting of April 30, 2021

Read More...

AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities

May 2nd, 2021 1:53 am

Read more:
AB Science reports today its annual financials as of 31 December 2020 and provides an update on its activities

Read More...

PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE study

May 2nd, 2021 1:53 am

Oslo (Norway), 30 April 2021 – PCI Biotech (OSE: PCIB), a clinical-stage biopharma company developing innovative therapeutics that address significant unmet medical needs in cancer today announced that the first US patient has been enrolled into the fimaChem pivotal RELEASE study with registration intent in inoperable bile duct cancer patients. The RELEASE study spans across Europe, USA and Asia, with patient enrolment initiated in all continents.

Continue reading here:
PCI Biotech: First US patient enrolled in the fimaChem pivotal RELEASE study

Read More...

Galapagos creates new subscription right plans

May 2nd, 2021 1:53 am

Mechelen, Belgium; 30 April 2021, 22.01 CET; regulated information –– Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 2,736,250 subscription rights under new subscription right plans for the benefit of the personnel of the company and its subsidiaries.

Continue reading here:
Galapagos creates new subscription right plans

Read More...

Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and…

May 2nd, 2021 1:53 am

Data demonstrate strong sensitivity and negative predictive value (NPV) Data demonstrate strong sensitivity and negative predictive value (NPV)

See the original post:
Progenity Presents Key Verification Study Data for Preecludia™ Preeclampsia Rule-out Test at the 2021 American College of Obstetricians and...

Read More...

ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 – May 2, 2021

May 2nd, 2021 1:53 am

GENEVA, Switzerland and BOSTON, MA – April 30, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN) a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of five e-Posters on linzagolix in the treatment of uterine fibroids at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting (ACSM), which will take place virtually from April 30 to May 2, 2021.

View original post here:
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021

Read More...

ECMOHO Announces Fourth Quarter Unaudited Financial Results and Fiscal Year 2020 Audited Financial Results

May 2nd, 2021 1:53 am

SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- ECMOHO Limited (Nasdaq: MOHO) (“ECMOHO” or the “Company”), a leading integrated solutions provider in the non-medical health and wellness market in China, today announced its audited financial results for the fiscal year ended December 31, 2020.

Read the original post:
ECMOHO Announces Fourth Quarter Unaudited Financial Results and Fiscal Year 2020 Audited Financial Results

Read More...

AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020

May 2nd, 2021 1:53 am

SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (the “SEC”) on April 30, 2021.

Read this article:
AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020

Read More...

Blueberries Medical Reports 2020 Financial Results

May 2nd, 2021 1:53 am

TORONTO, April 30, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or “Blueberries”), is pleased to report its financial results for the year ended December 31, 2020. Blueberries has filed today its audited consolidated financial statements and related management’s discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Excerpt from:
Blueberries Medical Reports 2020 Financial Results

Read More...

Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

May 2nd, 2021 1:53 am

SUZHOU and SHANGHAI, China, April 30, 2021 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it will participate in the following upcoming virtual conferences:

See the rest here:
Gracell Biotechnologies to Participate in Upcoming Virtual Conferences in May

Read More...

Shattuck Labs Announces Participation in Upcoming May Conferences

May 2nd, 2021 1:53 am

AUSTIN, TX and DURHAM, NC, April 30, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer, will participate in two upcoming conferences.

Link:
Shattuck Labs Announces Participation in Upcoming May Conferences

Read More...

Page 223«..1020..222223224225..230240..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick